Celcuity Announces Clinically Meaningful Improvement in Both Progression-Free Survival (“PFS”) ...

Celcuity eyes big market opportunity after breast cancer win

Celcuity shares rocket on a big win for its lead drug gedatolisib in advanced breast cancer, catapulting its value to almost $1.4 billion.

Celcuity rockets after positive trial results on breast cancer combo treatment

The company currently has no drugs on the market and has reported no revenue....

Celcuity shares triple on late-stage results for breast cancer therapy

Trial data showed the drug dramatically reduced cancer progression risk in certain patients, supporting Celcuity’s plans to soon file for approval.

Celcuity Announces Clinically Meaningful Improvement in Both Progression-Free Survival (“PFS”) ...

Hazard Ratios and Improvements in Median PFS are

Celcuity Announces Clinically Meaningful Improvement in Both Progression-Free Survival (“PFS”) Primary Endpoints from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Trial

Hazard Ratios and Improvements in Median PFS areUnprecedented in HR+/HER2- Advanced Breast Cancer (“ABC”) Gedatolisib + palbociclib + fulvestrant...

Gedatolisib Shows Impressive PFS in HR+/HER2– Breast Cancer

New clinical trial results reveal gedatolisib significantly improves progression-free survival in advanced HR+/HER2– breast cancer, offering hope for patients.